Esperion Therapeutics Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 1.26
Dividend & YieldN/A$ (N/A)
Beta 0.31
Market capitalization 481.89M
Operating cash flow -190.06M
ESG Scores unknown

Company description

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Sector: Healthcare - Industry: Drug Manufacturers—Specialty & Generic

Financial Ratios
Quick Ratio4.02
Working Capital-1.05
Return On Equity1.37
Debt To Equity-2.56
Fixed Asset Ratio0
Fixed Interest Cover-4.61

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 24.45M -13.9M 22.62M -29.44M
Total Cashflows From Investing Activities 140.45M 64.23M 21.36M -50.48M
Net Borrowings -1.05M 280M 280M
Total Cash From Financing Activities 10.69M 136.19M 201.72M 268.22M
Change To Operating Activities 4.71M 6.6M 1.65M 5.74M
Issuance Of Stock 11.74M 11.77M 6.63M 222.45M
Net Income -201.81M -97.17M -143.55M -269.11M
Change In Cash 2.5M 130.09M 137.9M -46.07M
Effect Of Exchange Rate
Total Cash From Operating Activities -148.64M -70.34M -85.18M -263.81M
Depreciation 265k 319k 547k 612k
Change To Account Receivables -12.39M -12.39M -12.39M -10.55M
Other Cashflows From Financing Activities 124.42M 124.42M -29.91M 45.77M
Change To Netincome 23.75M 33.8M 60.35M 55.58M
Capital Expenditures -151k -953k -869k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development
Income Before Tax -201.81M -97.17M -143.55M -269.11M
Net Income -201.81M -97.17M -143.55M -269.11M
Selling General Administrative 33.1M 65.85M 199.62M 171.74M
Gross Profit -171.49M -27.25M 78.22M -41.74M
Ebit -204.59M -93.1M -121.4M -213.48M
Operating Income -204.59M -93.1M -121.4M -213.48M
Interest Expense -28k -8.12M -22.67M -46.35M
Income Tax Expense
Total Revenue 148.36M 227.55M 78.45M
Cost Of Revenue 171.49M 175.61M 149.33M 120.19M
Total Other Income ExpenseNet 2.77M -4.06M -22.16M -55.63M
Net Income From Continuing Ops -201.81M -97.17M -143.55M -269.11M
Net Income Applicable To Common Shares -201.81M -97.17M -143.55M -269.11M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 64.33M 194.5M 449.39M 578.53M
Total Stockholder Equity 79.12M 19.95M -96.13M -196.94M
Other Current Liabilities 2.15M 6.69M 21.88M
Total Assets 143.45M 214.45M 353.26M 381.59M
Common Stock 27k 27k 26k 61k
Other Current Assets 928k
Retained Earnings -598.1M -695.27M -838.82M -1.11B
Treasury Stock -319k 23k -55M -55.03M
Cash 36.97M 166.13M 304.96M 208.89M
Total Current Liabilities 64.33M 66.08M 94.07M 73.35M
Other Stockholder Equity -319k 23k -31k
Property, Plant, and Equipment 520k 2.68M 7.31M 2.56M
Total Current Assets 142.63M 211.71M 345.9M 328.97M
Net Tangible Assets 79.06M 19.89M -96.19M -197M
Net Receivables 12.39M 22.93M
Accounts Payable 44.89M 28.86M 51.98M 17.56M


Insider Transactions

Here are the insider transactions of stock shares related to Esperion Therapeutics Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
FOODY JOANNE MICALESale at price 7.69 per share.D2022-10-18Officer942
WARREN ERICSale at price 7.69 per share.D2022-10-18Officer107
KOENIG SHELDON LSale at price 6.94 per share.D2022-09-19Chief Executive Officer3.39k
WARREN ERICSale at price 6.92 per share.D2022-09-19Officer255
WARREN ERICPurchase at price 7.46 per share.D2022-08-31Officer1k
WARREN ERICSale at price 6.81 per share.D2022-08-17Officer199
KOENIG SHELDON LPurchase at price 5.80 per share.D2022-08-05Chief Executive Officer8.61k
FOODY JOANNE MICALESale at price 6.55 per share.D2022-07-19Officer3.9k
WARREN ERICSale at price 6.58 per share.D2022-07-19Officer431
KOENIG SHELDON LSale at price 4.99 per share.D2022-06-17Chief Executive Officer4.55k
WARREN ERICSale at price 4.90 per share.D2022-06-17Officer256
CARROLL J MARTINPurchase at price 5.64 per share.D2022-06-02Director5k
WARREN ERICSale at price 5.98 per share.D2022-05-17Officer196
KOENIG SHELDON LSale at price 4.58 per share.D2022-03-17Chief Executive Officer571
BARTRAM RICHARD BStock Award(Grant) at price 0.00 per share.D2022-03-14Chief Financial Officer37k
KOENIG SHELDON LStock Award(Grant) at price 0.00 per share.D2022-03-14Chief Executive Officer116k
FOODY JOANNE MICALEStock Award(Grant) at price 0.00 per share.D2022-03-14Officer28k
WARREN ERICStock Award(Grant) at price 0.00 per share.D2022-03-14Officer13k
LOOKER BENJAMINStock Award(Grant) at price 0.00 per share.D2022-01-27General Counsel70.8k
BARTRAM RICHARD BStock Award(Grant) at price 0.00 per share.D2021-10-29Chief Financial Officer18.7k
KOENIG SHELDON LStock Award(Grant) at price 0.00 per share.D2021-10-29Chief Executive Officer26.7k
FOODY JOANNE MICALEStock Award(Grant) at price 0.00 per share.D2021-10-29Officer22.45k
FOODY JOANNE MICALEStock Award(Grant) at price 0.00 per share.D2021-06-28Officer62.53k
GOTTO ANTONIO M JRStock Award(Grant) at price 0.00 per share.D2021-05-27Director12.38k
VITULLO NICOLEStock Award(Grant) at price 0.00 per share.D2021-05-27Director12.38k
MCGOVERN MARK EStock Award(Grant) at price 0.00 per share.D2021-05-27Director12.38k
SHEPARD JAY PStock Award(Grant) at price 0.00 per share.D2021-05-27Director12.38k
JANNEY DANIEL SPENCERStock Award(Grant) at price 0.00 per share.D2021-05-27Director12.38k
BERKOWITZ JEFFREYStock Award(Grant) at price 0.00 per share.D2021-05-27Director12.38k
WOODY TRACY MStock Award(Grant) at price 0.00 per share.D2021-05-27Director12.38k
FUHRMAN ALANStock Award(Grant) at price 0.00 per share.D2021-05-27Director12.38k
BIOTECH TARGET N.VPurchase at price 20.22 per share.D2021-05-24Beneficial Owner of more than 10% of a Class of Security100k
BIOTECH TARGET N VPurchase at price 20.22 per share.D2021-05-24Beneficial Owner of more than 10% of a Class of Security100k
BIOTECH TARGET N.VPurchase at price 20.37 per share.D2021-05-19Beneficial Owner of more than 10% of a Class of Security200k
BIOTECH TARGET N VPurchase at price 20.37 per share.D2021-05-19Beneficial Owner of more than 10% of a Class of Security200k
KOENIG SHELDON LStock Award(Grant) at price 0.00 per share.D2021-05-17Chief Executive Officer20k
BIOTECH TARGET N.VPurchase at price 20.02 - 20.57 per share.I2021-05-06Beneficial Owner of more than 10% of a Class of Security230k
BIOTECH TARGET N VPurchase at price 20.02 - 20.57 per share.I2021-05-06Beneficial Owner of more than 10% of a Class of Security230k
BARTRAM RICHARD BStock Award(Grant) at price 0.00 per share.D2021-01-28Chief Financial Officer5k
KOENIG SHELDON LStock Award(Grant) at price 0.00 per share.D2021-01-28Chief Operating Officer30k
HALL ASHLEYStock Award(Grant) at price 0.00 per share.D2021-01-28Officer7k
MAYLEBEN TIMOTHY MConversion of Exercise of derivative security at price 2.10 per share.D2020-12-30Chief Executive Officer10.7k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Esperion Therapeutics Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Esperion Therapeutics Inc

Here is the result of two systematic investment strategies applied to Esperion Therapeutics Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Esperion Therapeutics Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Esperion Therapeutics Inc:

Esperion Therapeutics Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -74.85% on the backtest period.

Performance at glance

Performance

-74.85 %

Latent gain

-1261.93 $

Invested capital

1685.87 $

Annualized return

-18.26 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Esperion Therapeutics Inc

This is the result of two momentum investment strategies applied to Esperion Therapeutics Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Esperion Therapeutics Inc

The following chart shows all the entries opened by the momentum investment system on Esperion Therapeutics Inc:

Esperion Therapeutics Inc momentum entries
  • The first momentum investment strategy would give -63.37% of return on Esperion Therapeutics Inc. That represents -2897.91$ of latent gain with 4572.99$ of employed capital.
  • The second momentum investment strategy would give -72.72% of return on Esperion Therapeutics Inc. That represents -2314.98$ of latent gain with 3183.54$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-63.37 %

Latent gain

-2897.91 $

Invested capital

4572.99 $

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

-72.72 %

Latent gain

-2314.98 $

Invested capital

3183.54 $

Annualized return

-20.09 %

Momentum equity curve on Esperion Therapeutics Inc

The following chart shows the equity curve of the two momentum strategies applied to Esperion Therapeutics Inc:

Esperion Therapeutics Inc momentum equity

Note: the dividends potentially given by Esperion Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Esperion Therapeutics Inc

The following chart shows the employed capital evolution of the two momentum strategies on Esperion Therapeutics Inc since the beginning:

Esperion Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Esperion Therapeutics Inc

Buy the dip entry openings on Esperion Therapeutics Inc

Esperion Therapeutics Inc

The performance achieved by the robo-advisor on Esperion Therapeutics Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows Esperion Therapeutics Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Esperion Therapeutics Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %

Equity curve of the strategy applied to Esperion Therapeutics Inc

The following chart shows the result of the investment strategy applied to Esperion Therapeutics Inc:

Esperion Therapeutics Inc

Note: the dividends potentially given by Esperion Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Esperion Therapeutics Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Esperion Therapeutics Inc:

Esperion Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Esperion Therapeutics Inc

In this section, I will compare the three previous investment strategies applied to Esperion Therapeutics Inc.

Equity curve comparison on Esperion Therapeutics Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Esperion Therapeutics Inc investment strategy comparison

Employed capital comparison on Esperion Therapeutics Inc

Esperion Therapeutics Inc investment comparison

Performance comparison on Esperion Therapeutics Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -74.85% -1261.93$ 1685.87$ -18.26%
Momentum 1 quarter -63.37% -2897.91$ 4572.99$ -16.42%
Momentum 2 quarters -72.72% -2314.98$ 3183.54$ -20.09%
Non-directional 0% 0.0$ 0.0$ 0.0%
Annualized return comparison

Automatic investment

-18.26 %

Momentum 1Q

-20.09 %

Momentum 2Q

-20.09 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Esperion Therapeutics Inc:

Positive correlations

Most correlated stocks this year

  • Esperion Therapeutics Inc

  • Most correlated stocks last 3 months

  • Myomo Inc
  • Nektar Therapeutics
  • Esperion Therapeutics Inc
  • BUKIT SEMBAWANG

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months


    Note: The algorithm computes the probability of correlation between Esperion Therapeutics Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Esperion Therapeutics Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Esperion Therapeutics Inc
    Country United States
    City Ann Arbor
    Address 3891 Ranchero Drive
    Phone 734 887 3903
    Website www.esperion.com
    FullTime employees 218
    Industry Drug Manufacturers—Specialty & Generic
    Sector Healthcare
    Exchange XNAS
    Ticker ESPR
    Market www.nasdaq.com

    Esperion Therapeutics Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown